<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Artiva Biotherapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock</link>
<description>Latest news and press releases for Artiva Biotherapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 08 May 2026 10:52:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/artiva-biotherapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835483478dffbe2df0e3b95.webp</url>
<title>Artiva Biotherapeutics, Inc.</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock</link>
</image>
<item>
<title>Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-pricing-of-dollar300-million-underwritten-offering-of-common-stock-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-pricing-of-dollar300-million-underwritten-offering-of-common-stock-and-pre-funded-warrants</guid>
<pubDate>Fri, 08 May 2026 10:52:00 GMT</pubDate>
<description>SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the pricing of an underwritten offering of 23,871,526 shares of its common stock at a price of $11.52 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 2,170,138 shares</description>
</item>
<item>
<title>Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a panel as well as a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 2:15 p.m. EDT. To access the audio webcast and su</description>
</item>
<item>
<title>Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-reports-full-year-2025-financial-results-and-recent-business-highlights-9</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-reports-full-year-2025-financial-results-and-recent-business-highlights-9</guid>
<pubDate>Tue, 10 Mar 2026 20:05:00 GMT</pubDate>
<description>Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026 Strengthened board and executive leadership with deep immunology, commercial and financial expertise Robust balance sheet with cash, cash equivalents and investments of $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027</description>
</item>
<item>
<title>Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Wed, 25 Feb 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA. Members of the Artiva management team will als</description>
</item>
<item>
<title>Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-appointment-of-thad-huston-as-chief-financial-officer-and-award-of-inducement-grant</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-appointment-of-thad-huston-as-chief-financial-officer-and-award-of-inducement-grant</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to</description>
</item>
<item>
<title>Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-appointment-of-elaine-sorg-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-appointment-of-elaine-sorg-to-board-of-directors</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to</description>
</item>
<item>
<title>Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-upcoming-presentations-130000915</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-upcoming-presentations-130000915</guid>
<pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a</description>
</item>
<item>
<title>Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-positive-initial-122000911</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-positive-initial-122000911</guid>
<pubDate>Wed, 12 Nov 2025 12:20:00 GMT</pubDate>
<description>32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial sites with no specialized oncology oversight, demonstrating the feasibility of administering this regimen outside the hospital setting No cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) Consistent and complete</description>
</item>
<item>
<title>Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-reports-third-quarter-120000055</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-reports-third-quarter-120000055</guid>
<pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
<description>Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, the first known therapy within the emerging deep B-cell depletion category to receive this designation in RA Company to host webcast later this morning to discuss initial safety and translational data from clinical trials evaluating AlloNK in combination with anti-CD20 monoclonal antibodies across au</description>
</item>
<item>
<title>Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-host-virtual-event-210500815</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-host-virtual-event-210500815</guid>
<pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
<description>The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a favorable tolerability profile observed to date and the feasibility of patient management in outpatient rheumatology clinics Initial translational data highlighting uniform, consistent, deep B-cell depletion supporting AlloNK’s intended mechanism of action SAN DIEGO, Nov. 03, 2025 (GLOBE</description>
</item>
<item>
<title>Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-participate-upcoming-investor-201700131</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-participate-upcoming-investor-201700131</guid>
<pubDate>Thu, 30 Oct 2025 20:17:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate at the following investor conferences: TD Cowen's Immunology & Inflammation Summit (Virtual) - fireside chat on Wednesday, November 12, 2025, at 11:30 a.m. ET 2025 Jefferies Global Hea</description>
</item>
<item>
<title>Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-refractory-rheumatoid-200500522</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-refractory-rheumatoid-200500522</guid>
<pubDate>Thu, 16 Oct 2025 20:05:00 GMT</pubDate>
<description>Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep B-cell depleting category to receive this designation with the potential to become the first in the category to advance to a pivotal trial in RA, pending FDA feedback expected in 1H 2026 Continued execution and enrollment progress with more than 20 patients treated with AlloNK + monoclo</description>
</item>
<item>
<title>Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-participate-cantor-global-200500436</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-participate-cantor-global-200500436</guid>
<pubDate>Mon, 25 Aug 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:45 a.m. EDT. Members of the Artiva management team will also be available to pa</description>
</item>
<item>
<title>Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-reports-second-quarter-200500661</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-reports-second-quarter-200500661</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with over a dozen patients treated with AlloNK + mAb across over a dozen sites in company-sponsored and investigator-initiated clinical trials in autoimmune diseases Initial safety, translational data, and lead indication selection for AlloNK in aut</description>
</item>
<item>
<title>Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-participate-jefferies-global-200500268</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-participate-jefferies-global-200500268</guid>
<pubDate>Wed, 28 May 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT. Members of the Artiva management team will also be available to participat</description>
</item>
<item>
<title>Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-longer-term-200500159</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-announces-longer-term-200500159</guid>
<pubDate>Tue, 13 May 2025 20:05:00 GMT</pubDate>
<description>64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of response for AlloNK + rituximab not yet reached and is at least 19.4 months, in line with approved auto-CAR-T therapies in aggressive B-NHL AlloNK’s activity and well-tolerated safety profile in aggressive B-NHL patients support the potential to deliver deep B-cell depletion in a ref</description>
</item>
<item>
<title>Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-reports-first-quarter-120000744</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-reports-first-quarter-120000744</guid>
<pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
<description>IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren’s disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer</description>
</item>
<item>
<title>Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-present-longer-term-203500617</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-present-longer-term-203500617</guid>
<pubDate>Mon, 28 Apr 2025 20:35:00 GMT</pubDate>
<description>Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell th</description>
</item>
<item>
<title>Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-appoints-subhashis-banerjee-200500806</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-appoints-subhashis-banerjee-200500806</guid>
<pubDate>Tue, 08 Apr 2025 20:05:00 GMT</pubDate>
<description>Dr. Banerjee’s appointment culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapySAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical O</description>
</item>
<item>
<title>Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-participate-24th-annual-200500494</link>
<guid isPermaLink="true">https://6ix.com/company/artiva-biotherapeutics-inc-common-stock/news/artiva-biotherapeutics-participate-24th-annual-200500494</guid>
<pubDate>Mon, 31 Mar 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 11:00 a.m. EDT. Members of the Artiva management team will also be available to participate in invest</description>
</item>
</channel>
</rss>